These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36941652)

  • 1. No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients.
    Philippot Q; Bastard P; Puel A; Casanova JL; Cobat A; Laouénan C; Tardivon C; Crestani B; Borie R
    Respir Res; 2023 Mar; 24(1):87. PubMed ID: 36941652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia.
    Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A
    J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital.
    Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
    J Clin Immunol; 2022 Apr; 42(3):459-470. PubMed ID: 35083626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
    Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J
    J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs.
    Bastard P; Vazquez SE; Liu J; Laurie MT; Wang CY; Gervais A; Le Voyer T; Bizien L; Zamecnik C; Philippot Q; Rosain J; Catherinot E; Willmore A; Mitchell AM; Bair R; Garçon P; Kenney H; Fekkar A; Salagianni M; Poulakou G; Siouti E; Sahanic S; Tancevski I; Weiss G; Nagl L; Manry J; Duvlis S; Arroyo-Sánchez D; Paz Artal E; Rubio L; Perani C; Bezzi M; Sottini A; Quaresima V; Roussel L; Vinh DC; Reyes LF; Garzaro M; Hatipoglu N; Boutboul D; Tandjaoui-Lambiotte Y; Borghesi A; Aliberti A; Cassaniti I; Venet F; Monneret G; Halwani R; Sharif-Askari NS; Danielson J; Burrel S; Morbieu C; Stepanovskyy Y; Bondarenko A; Volokha A; Boyarchuk O; Gagro A; Neuville M; Neven B; Keles S; Hernu R; Bal A; Novelli A; Novelli G; Saker K; Ailioaie O; Antolí A; Jeziorski E; Rocamora-Blanch G; Teixeira C; Delaunay C; Lhuillier M; Le Turnier P; Zhang Y; Mahevas M; Pan-Hammarström Q; Abolhassani H; Bompoil T; Dorgham K; ; ; ; Gorochov G; Laouenan C; Rodríguez-Gallego C; Ng LFP; Renia L; Pujol A; Belot A; Raffi F; Allende LM; Martinez-Picado J; Ozcelik T; Imberti L; Notarangelo LD; Troya J; Solanich X; Zhang SY; Puel A; Wilson MR; Trouillet-Assant S; Abel L; Jouanguy E; Ye CJ; Cobat A; Thompson LM; Andreakos E; Zhang Q; Anderson MS; Casanova JL; DeRisi JL
    Sci Immunol; 2023 Dec; 8(90):eabp8966. PubMed ID: 35857576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital.
    Chauvineau-Grenier A; Bastard P; Servajean A; Gervais A; Rosain J; Jouanguy E; Cobat A; Casanova JL; Rossi B
    Res Sq; 2021 Oct; ():. PubMed ID: 34611657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Type I Interferon Signaling in Myeloid Cells by Autoantibodies in Severe COVID-19 Patients.
    Aoki A; Iwamura C; Kiuchi M; Tsuji K; Sasaki A; Hishiya T; Hirasawa R; Kokubo K; Kuriyama S; Onodera A; Shimada T; Nagaoka T; Ishikawa S; Kojima A; Mito H; Hase R; Kasahara Y; Kuriyama N; Nakamura S; Urushibara T; Kaneda S; Sakao S; Nishida O; Takahashi K; Kimura MY; Motohashi S; Igari H; Ikehara Y; Nakajima H; Suzuki T; Hanaoka H; Nakada TA; Kikuchi T; Nakayama T; Yokote K; Hirahara K
    J Clin Immunol; 2024 Apr; 44(4):104. PubMed ID: 38647550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies neutralizing type I IFNs are present in
    Bastard P; Gervais A; Le Voyer T; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; de Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs C; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; van de Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A; Kann NY; Shcherbina A; Lau YL; Leung D; Coulongeat M; Marlet J; Koning R; Reyes LF; Chauvineau-Grenier A; Venet F; Monneret G; Nussenzweig MC; Arrestier R; Boudhabhay I; Baris-Feldman H; Hagin D; Wauters J; Meyts I; Dyer AH; Kennelly SP; Bourke NM; Halwani R; Sharif-Askari NS; Dorgham K; Sallette J; Sedkaoui SM; AlKhater S; Rigo-Bonnin R; Morandeira F; Roussel L; Vinh DC; Ostrowski SR; Condino-Neto A; Prando C; Bonradenko A; Spaan AN; Gilardin L; Fellay J; Lyonnet S; Bilguvar K; Lifton RP; Mane S; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; Anderson MS; Boisson B; Béziat V; Zhang SY; Vandreakos E; Hermine O; Pujol A; Peterson P; Mogensen TH; Rowen L; Mond J; Debette S; de Lamballerie X; Duval X; Mentré F; Zins M; Soler-Palacin P; Colobran R; Gorochov G; Solanich X; Susen S; Martinez-Picado J; Raoult D; Vasse M; Gregersen PK; Piemonti L; Rodríguez-Gallego C; Notarangelo LD; Su HC; Kisand K; Okada S; Puel A; Jouanguy E; Rice CM; Tiberghien P; Zhang Q; Cobat A; Abel L; Casanova JL
    Sci Immunol; 2021 Aug; 6(62):. PubMed ID: 34413139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1.
    Bastard P; Orlova E; Sozaeva L; Lévy R; James A; Schmitt MM; Ochoa S; Kareva M; Rodina Y; Gervais A; Le Voyer T; Rosain J; Philippot Q; Neehus AL; Shaw E; Migaud M; Bizien L; Ekwall O; Berg S; Beccuti G; Ghizzoni L; Thiriez G; Pavot A; Goujard C; Frémond ML; Carter E; Rothenbuhler A; Linglart A; Mignot B; Comte A; Cheikh N; Hermine O; Breivik L; Husebye ES; Humbert S; Rohrlich P; Coaquette A; Vuoto F; Faure K; Mahlaoui N; Kotnik P; Battelino T; Trebušak Podkrajšek K; Kisand K; Ferré EMN; DiMaggio T; Rosen LB; Burbelo PD; McIntyre M; Kann NY; Shcherbina A; Pavlova M; Kolodkina A; Holland SM; Zhang SY; Crow YJ; Notarangelo LD; Su HC; Abel L; Anderson MS; Jouanguy E; Neven B; Puel A; Casanova JL; Lionakis MS
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33890986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
    Bastard P; Gervais A; Taniguchi M; Saare L; Särekannu K; Le Voyer T; Philippot Q; Rosain J; Bizien L; Asano T; Garcia-Prat M; Parra-Martínez A; Migaud M; Tsumura M; Conti F; Belot A; Rivière JG; Morio T; Tanaka J; Javouhey E; Haerynck F; Duvlis S; Ozcelik T; Keles S; Tandjaoui-Lambiotte Y; Escoda S; Husain M; Pan-Hammarström Q; Hammarström L; Ahlijah G; Abi Haidar A; Soudee C; Arseguel V; Abolhassani H; Sahanic S; Tancevski I; Nukui Y; Hayakawa S; Chrousos GP; Michos A; Tatsi EB; Filippatos F; Rodriguez-Palmero A; Troya J; Tipu I; Meyts I; Roussel L; Ostrowski SR; Schidlowski L; Prando C; Condino-Neto A; Cheikh N; Bousfiha AA; El Bakkouri J; ; ; ; Peterson P; Pujol A; Lévy R; Quartier P; Vinh DC; Boisson B; Béziat V; Zhang SY; Borghesi A; Pession A; Andreakos E; Marr N; Mentis AA; Mogensen TH; Rodríguez-Gallego C; Soler-Palacin P; Colobran R; Tillmann V; Neven B; Trouillet-Assant S; Brodin P; Abel L; Jouanguy E; Zhang Q; Martinón-Torres F; Salas A; Gómez-Carballa A; Gonzalez-Granado LI; Kisand K; Okada S; Puel A; Cobat A; Casanova JL
    J Exp Med; 2024 Feb; 221(2):. PubMed ID: 38175961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against type I IFNs in patients with life-threatening COVID-19.
    Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; D'Angio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; ; ; ; ; ; ; ; ; ; ; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL
    Science; 2020 Oct; 370(6515):. PubMed ID: 32972996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial.
    Alotaibi F; Alharbi NK; Rosen LB; Asiri AY; Assiri AM; Balkhy HH; Al Jeraisy M; Mandourah Y; AlJohani S; Al Harbi S; Jokhdar HAA; Deeb AM; Memish ZA; Jose J; Ghazal S; Al Faraj S; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; AlMutairi BM; Al-Dawood A; Abdullah ML; Barhoumi T; Alenazi MW; Almasood A; Holland SM; Arabi YM;
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13116. PubMed ID: 36960162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human autoantibodies neutralizing type I IFNs: From 1981 to 2023.
    Bastard P; Gervais A; Le Voyer T; Philippot Q; Cobat A; Rosain J; Jouanguy E; Abel L; Zhang SY; Zhang Q; Puel A; Casanova JL
    Immunol Rev; 2024 Mar; 322(1):98-112. PubMed ID: 38193358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies.
    Damoiseaux J; Dotan A; Fritzler MJ; Bogdanos DP; Meroni PL; Roggenbuck D; Goldman M; Landegren N; Bastard P; Shoenfeld Y; Conrad K
    Autoimmun Rev; 2022 Mar; 21(3):103012. PubMed ID: 34896650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insufficient type I IFN immunity underlies life-threatening COVID-19 pneumonia.
    Bastard P; Zhang Q; Cobat A; Jouanguy E; Zhang SY; Abel L; Casanova JL
    C R Biol; 2021 Jun; 344(1):19-25. PubMed ID: 34213846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
    de Prost N; Bastard P; Arrestier R; Fourati S; Mahévas M; Burrel S; Dorgham K; Gorochov G; Tandjaoui-Lambiotte Y; Azzaoui I; Fernandes I; Combes A; Casanova JL; Mekontso-Dessap A; Luyt CE
    J Clin Immunol; 2021 Apr; 41(3):536-544. PubMed ID: 33616813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure.
    Ghale R; Spottiswoode N; Anderson MS; Mitchell A; Wang G; Calfee CS; DeRisi JL; Langelier CR
    Respir Res; 2022 Dec; 23(1):354. PubMed ID: 36527083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain.
    Troya J; Bastard P; Planas-Serra L; Ryan P; Ruiz M; de Carranza M; Torres J; Martínez A; Abel L; Casanova JL; Pujol A
    J Clin Immunol; 2021 Jul; 41(5):914-922. PubMed ID: 33851338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia.
    Vanker M; Särekannu K; Fekkar A; Jørgensen SE; Haljasmägi L; Kallaste A; Kisand K; Lember M; Peterson P; Menon M; Hussell T; Knight S; Moore-Stanley J; Bastard P; Zhang SY; Mogensen TH; Philippot Q; Zhang Q; Puel A; Casanova JL; Kisand K
    J Interferon Cytokine Res; 2023 Sep; 43(9):379-393. PubMed ID: 37253131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study.
    Arrestier R; Bastard P; Belmondo T; Voiriot G; Urbina T; Luyt CE; Gervais A; Bizien L; Segaux L; Ben Ahmed M; Bellaïche R; Pham T; Ait-Hamou Z; Roux D; Clere-Jehl R; Azoulay E; Gaudry S; Mayaux J; Fage N; Ait-Oufella H; Moncomble E; Parfait M; Dorgham K; Gorochov G; Mekontso-Dessap A; Canoui-Poitrine F; Casanova JL; Hue S; de Prost N
    Ann Intensive Care; 2022 Dec; 12(1):121. PubMed ID: 36586050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.